(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 April 2009 (09.04.2009)

PCT

(10) International Publication Number
WO 2009/045831 A1

(51) International Patent Classification:
C07D 213/64 (2006.01) *A61P 3/10* (2006.01)
A61K 31/4418 (2006.01)

(21) International Application Number:
PCT/US2008/077626

(22) International Filing Date:
25 September 2008 (25.09.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/975,865 28 September 2007 (28.09.2007) US

(71) Applicant *(for all designated States except US)*: **SMITHKLINE BEECHAM CORPORATION** [US/US]; One Franklin Plaza, PO Box 7929, Philadelphia, PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BANKER, Pierette** [US/US]; c/o GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 (US). **DICKERSON, Scott Howard** [US/US]; c/o GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709-3398 (US). **GARRIDO, Dulce Maria** [US/US]; c/o GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 (US). **SPARKS, Steven Meagher** [US/US]; c/o GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 (US). **TAVARES, Francis X** [IN/US]; c/o GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, P.O Box 13398, Research Triangle Park, NC 27709-3398 (US). **THOMSON, Stephen Andrew** [US/US]; c/o GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, P.O. Box 13398, Research Triangle Park, NC 27709-3398 (US).

(74) Agents: **DEPPENBROCK, Bonnie L.** et al.; GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(54) Title: GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF

(57) Abstract: This invention relates to a novel compound which is a glycogen phosphorylase inhibitor and its use in the treatment of diabetes and other conditions associated therewith. The invention further relates to a pharmaceutical composition containing the compound and to processes for preparing the compound and pharmaceutical composition.

WO 2009/045831 A1